logo phoenix Investor Center

Investor Center | Company News | Annual Reports | Stock Information | Historic Stock Lookup | SEC Filings |
Printer Friendly Page
Email This Page
Corporate Governance | Email Alerts

Company News

  
All Releases
View Summary Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Jul 17, 2008 		PDF 22.6 KB
View Summary Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Jul 9, 2008 		PDF 25.2 KB
View Summary Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Jun 25, 2008 		PDF 26.1 KB
View Summary Craig Johnson Joins Ardea Biosciences' Board of Directors
Jun 12, 2008 		PDF 22.4 KB
View Summary Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
Jun 11, 2008 		PDF 25.7 KB
View Summary Ardea to Present Data on Inflammation Programs at 2008 Annual European Congress of Rheumatology
Jun 5, 2008 		PDF 23.2 KB
View Summary Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
May 22, 2008 		PDF 24.6 KB
View Summary Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
May 20, 2008 		PDF 26.4 KB
View Summary Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
May 19, 2008 		PDF 25.6 KB
View Summary Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
May 14, 2008 		PDF 22.2 KB
Showing 1-10 of 49 releases Page: 1 2 3 4 5  See Next 10
RDEA - (NASD)
$13.84   + 0.62 		Jul 25, 2008
4:00 PM ET*